Compare VPG & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VPG | CTNM |
|---|---|---|
| Founded | 2009 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.5M | 489.4M |
| IPO Year | 2010 | 2024 |
| Metric | VPG | CTNM |
|---|---|---|
| Price | $126.19 | $12.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $53.50 | $19.00 |
| AVG Volume (30 Days) | ★ 652.6K | 149.3K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $307,202,000.00 | N/A |
| Revenue This Year | $7.21 | N/A |
| Revenue Next Year | $6.92 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.22 | N/A |
| 52 Week Low | $25.49 | $3.57 |
| 52 Week High | $136.21 | $16.33 |
| Indicator | VPG | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 76.00 | 42.61 |
| Support Level | $32.38 | $12.43 |
| Resistance Level | N/A | $13.26 |
| Average True Range (ATR) | 9.99 | 0.70 |
| MACD | 0.85 | -0.15 |
| Stochastic Oscillator | 78.55 | 14.94 |
Vishay Precision Group Inc manufactures and markets sensors and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.